A vertical strip on the left side of the cover features a microscopic image of endocrine cells. The cells are stained with various colors: bright green for cytoplasm and organelles, magenta for nuclei, and small red dots scattered throughout. The background of the entire cover is a dark blue with a faint, repeating pattern of the same microscopic image.

The Endocrine System at a Glance

Third Edition

**Ben Greenstein
Diana Wood**



 **WILEY-BLACKWELL**

The Endocrine System at a Glance

The Endocrine System at a Glance

Ben Greenstein

BA (Hons) PhD
Senior Visiting Research Fellow
Pain Management Unit
Royal Free School of Medicine
London
UK

Diana Wood

MA MD FRCP
Director of Medical Education and Clinical Dean
University of Cambridge School of Clinical Medicine
Clinical School
Addenbrooke's Hospital
Cambridge
UK

Third edition

 **WILEY-BLACKWELL**
A John Wiley & Sons, Ltd., Publication

This edition first published 2011 © 2011 by Ben Greenstein and Diana Wood
First edition 1994
Second edition 2006

Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley's global Scientific, Technical and Medical business with Blackwell Publishing.

Registered office: John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial offices: 9600 Garsington Road, Oxford, OX4 2DQ, UK
The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK
111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell.

The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

Library of Congress Cataloging-in-Publication Data

Greenstein, Ben, 1941-

The endocrine system at a glance / Ben Greenstein, Diana Wood. – 3rd ed.

p. ; cm. – (At a glance series)

Includes index.

ISBN-13: 978-1-4443-3215-5 (pbk. : alk. paper)

ISBN-10: 1-4443-3215-5

1. Endocrinology. I. Wood, Diana F. II. Title. III. Series: At a glance series (Oxford, England)

[DNLM: 1. Endocrine Glands–physiology. 2. Endocrine Glands–physiopathology. 3. Endocrine System Diseases. 4. Hormones–secretion. WK 100]

QP187.G834 2011

612.4–dc22

2011007204

A catalogue record for this book is available from the British Library.

Set in 9.5/12 pt Times-Roman by Toppan Best-set Premedia Limited

Contents

- Preface to the Third Edition 6
Preface to the First Edition 7
- Part 1 Fundamentals**
1. Introduction 8
 2. Chemical transmission 10
 3. Mechanisms of hormone action:
I Membrane receptors 12
 4. Mechanisms of hormone action:
II Intracellular receptors 14
 5. The hypothalamus and pituitary gland 16
 6. Gonadotrophin-releasing hormone: a peptide hormone 18
 7. Principles of feedback control 20
 8. Endocrine function tests 22
- Part 2 Growth**
9. Growth: I Cellular growth factors 24
 10. Growth: II Normal growth 26
 11. Growth: III Growth hormone 28
 12. Growth: IV Pathophysiology 30
- Part 3 Thyroid**
13. Thyroid: I Thyroid gland and thyroid hormones 32
 14. Thyroid: II Thyroid hormone secretion and action 34
 15. Thyroid: III Thyroid pathophysiology 36
- Part 4 Adrenals and autoimmunity**
16. Adrenal gland: I Adrenal medulla 38
 17. Adrenal gland: II Adrenocortical hormones 40
 18. Adrenal gland: III Adrenocorticotrophic hormone (ACTH) 42
 19. Adrenal gland: IV Cortisol and androgens 44
 20. Adrenal gland: V Aldosterone 46
 21. Adrenal gland: VI Pathophysiology 48
 22. Endocrine autoimmunity 50
- Part 5 Sexual differentiation and development**
23. Sexual differentiation and development:
I Introduction 52
 24. Sexual differentiation and development: II Puberty 54
- Part 6 Female reproduction**
25. Female reproduction: I Menstrual cycle 56
 26. Female reproduction: II Ovarian steroids 58
 27. Female reproduction: III Pregnancy 60
 28. Female reproduction: IV Parturition and lactation 62
 29. Female reproduction: V Pathophysiology 64
 30. Female reproduction: VI Contraception 66
- Part 7 Male reproduction**
31. Male reproduction: I The testis 68
 32. Male reproduction: II Actions of androgens 70
 33. Male reproduction: III Pathophysiology 72
- Part 8 Posterior pituitary hormones, salt and water balance and hypertension**
34. Oxytocin 74
 35. Vasopressin 76
 36. Renin–angiotensin–aldosterone system 78
 37. Endocrine hypertension 80
- Part 9 Metabolic endocrinology: Pancreas and gastrointestinal tract**
38. Insulin: I The pancreas and insulin secretion 82
 39. Insulin: II Insulin action 84
 40. Insulin: III Type 1 diabetes mellitus 86
 41. Insulin: IV Type 2 diabetes mellitus 88
 42. Glucagon 90
 43. Gastrointestinal hormones 92
- Part 10 Metabolic endocrinology: Energy homoeostasis and obesity**
44. Energy homoeostasis: I Summary 94
 45. Energy homoeostasis: II Central control 96
 46. Obesity: I Causes of obesity 98
 47. Obesity: II Cardiovascular and respiratory complications 100
 48. Obesity: III Insulin resistance and endocrine complications 102
- Part 11 Calcium and metabolic bone disease**
49. Calcium: I Parathyroid hormone 104
 50. Calcium: II Calcitonin 106
 51. Calcium: III Vitamin D 108
 52. Bone remodelling 110
 53. Metabolic bone disease: I Paget’s disease 112
 54. Metabolic bone disease:
II Primary osteoporosis 114
 55. Metabolic bone disease: III Secondary osteoporosis 116
- Part 12 Self assessment**
- MCQs 118
Answers 133
- Appendix: Normal Values 136
Glossary 137
Index 139

Preface to the Third Edition

The third edition of this book is again co-authored by Ben Greenstein and Diana Wood, a clinical endocrinologist. The book aims to relate basic endocrine sciences to the clinical background and presentations of disease and in keeping with the overall philosophy of the *At a Glance* series, and strives to present data in a varied way that facilitates rapid assimilation of the information. The book is aimed at undergraduate medical students, primarily in the early part of their course, although as a handy and accessible reference book and revision tool it should also be a useful source of information for clinical medical students and junior doctors. *The Endocrine System at a Glance*, as the name implies, does not claim to replace comprehensive textbooks; rather it serves as a concise guide and revision aid to this fascinating branch of clinical science and medicine. A new addition to the third edition is the presentation of revision questions relating to each chapter.

The authors have striven to present the data clearly and accurately, and every effort has been made to include information that is up-to-date at the time of going to press. We make no claim to infallibility, however, and if readers spot ambiguities, factual inaccuracies or typographical errors, we should be most grateful for feedback and for suggestions which will improve the book and the presentation of the information.

It remains for us to thank the many students and colleagues who have read and commented on the book while in draft form. It has been a pleasure to work with the staff at Wiley-Blackwell, and in particular Karen Moore and Beth Bishop, whose patience and guidance is much appreciated.

Ben Greenstein
Diana Wood
London and Cambridge

Preface to the First Edition

Endocrinology at a Glance published 1994

Endocrinology at a Glance is intended to be just that. It has been designed and written so that the diagrams and text complement each other, and both are to be consulted. The emphasis has been on the diagrams, and words have been kept to a minimum.

The book has been produced to provide as comprehensive an overview of the subject as any medical or science undergraduate student will need in order to pass and pass well an examination in basic endocrinology. In addition, it is hoped that *Endocrinology at a Glance* will be useful to students of clinical endocrinology who need to refer rapidly to the mechanisms underlying the subject. The book is not presented as an alternative to the several excellent textbooks of endocrinology, which serve as useful reference texts, and some of which have been used during the writing of this book.

Every attempt has been made to present the data accurately and to provide the most up-to-date and reliable information available. When speculative data are given, their fragility

has been indicated. Nevertheless, every writer, especially this one, is human and if the reader spots errors or a lack of clarity, or has any suggestions to improve or add to the presentation, this feedback will be gratefully appreciated and acknowledged.


I should like to thank the many undergraduate, medical, dental and science students who have scrutinized and used the diagrams, or similar ones, over the years, and whose criticisms have helped to make them more useful. I should like to thank Elizabeth Bridges, Kay Chan, Yacoub Dhaher, Munther Khamashta and Adam Greenstein for commentating on some of the work. It has been a pleasure working with the staff of Blackwell Science Ltd, and particularly Dr Stuart Taylor and Emma Lynch, whose friendly encouragement and advice cheered me on.

Ben Greenstein
London 1994

1

Introduction

(a) Examples of endocrine disorders throughout life



Clinical background

Endocrinology is the study of endocrine hormones and of the organs involved in endocrine hormone release. Classically, hormones have been described as chemical messengers, released and having their actions at distant sites. It is now clear, however, that there is a close relationship between hormones and other factors such as neurotransmitters and growth factors acting in a paracrine or autocrine fashion. Hormones are essential for the maintenance of normal physiological function and hormonal disorders occur at all stages of human life. Clinical endocrinologists thus look after patients of all ages and with a very wide range of disorders (Fig. 1a).

The principal endocrine glands

The brain is the controller of the nervous system, but it is also one of the most important endocrine glands. Specialized nerve cells, notably in the hypothalamus, synthesize hormones which are transported along the axon to the nerve terminal. Here they are released into the portal blood system, which carries them to the pituitary gland. In some cases, the axon of the neuroendocrine cell projects down to the pituitary cell itself. The principal hypothalamic neurohormones are:

1 corticotrophin-releasing hormone (CRH), controls the release of ACTH;

2 dopamine inhibits prolactin release;

3 growth-hormone-releasing hormone (GHRH) causes growth hormone release;

4 somatostatin inhibits growth hormone release;

5 gonadotrophin-releasing hormone (GnRH) causes luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release;

6 thyrotrophin-releasing hormone (TRH) causes thyroid-stimulating hormone (TSH) release;

7 oxytocin causes milk ejection and contraction of the uterus in labour – it is synthesized in the hypothalamus and is stored in and released from the posterior pituitary gland;

8 vasopressin (antidiuretic hormone, ADH) promotes water reabsorption from the kidney tubules – it is synthesized in the hypothalamus, and stored in and released from the posterior pituitary gland.

The pituitary gland is composed of two lobes, anterior and posterior, which arise from different embryological origins – the anterior originates from the embryonic oral cavity and the posterior from the base of the brain (i.e. a neural origin). The two lobes become closely apposed to each other to form the pituitary gland. Humans have a non-functional **intermediate lobe**, which is much larger in some other animals. The principal hormones of the pituitary are:

1 anterior:

- (a) **corticotrophin** (adrenocorticotrophic hormone; ACTH) releases glucocorticoids and other steroids from the adrenal cortex;
- (b) **follicle-stimulating hormone** (FSH) promotes spermatogenesis in males and ovarian follicular maturation in females;
- (c) **luteinizing hormone** (LH) promotes testosterone synthesis in males and causes ovarian follicular rupture and ovulation in females;
- (d) **prolactin** (PRL) promotes lactation and may have an immunomodulatory role in non-lactating females and males;
- (e) **thyrotrophin** (thyroid-stimulating hormone; TSH) promotes thyroid hormone production and release from the thyroid gland;
- (f) **growth hormone** (also called somatotrophin; GH) promotes muscle and skeletal growth.

2 posterior:

- (a) **oxytocin** causes milk ejection and contraction of the uterus in labour;
- (b) **vasopressin** (antidiuretic hormone, ADH) promotes water reabsorption from the renal tubules.

The thyroid gland is situated just in front of the trachea in humans. The thyroid-hormone-producing cells are arranged in follicles, and concentrate iodine which is used for the synthesis of the thyroid hormone. The circulating hormones are **thyroxine** (T₄) and **tri-iodothyronine** (T₃). **The parathyroid glands** are embedded in the thyroid, and produce **parathyroid hormone** (parathormone; PTH). PTH is important in the control of calcium and phosphate metabolism. **The parafollicular cells** are in the thyroid, scattered between the follicles. They produce **calcitonin**, which inhibits bone calcium resorption.

The adrenal glands are situated just above the kidneys, and are composed of an outer layer, or cortex, and an inner layer, or medulla (a modified ganglion). The hormones produced are:

1 cortex:

- (a) **glucocorticoids**, principally cortisol in humans, are involved in carbohydrate metabolism and the response to stress;
- (b) **mineralocorticoids**, principally aldosterone, control electrolyte balance;
- (c) **androgens**, principally testosterone, dehydroepiandrosterone sulphate (DHEAS) and 17-hydroxyprogesterone, modulate secondary sexual characteristics and have anabolic effects.

2 medulla:

- (a) **epinephrine** modulates cardiovascular and metabolic response to stress;
- (b) **norepinephrine**, principally a neurotransmitter in the peripheral sympathetic nervous system;
- (c) **dopamine**, a neurotransmitter in the autonomic nervous system.

The endocrine pancreas consists of islet cells scattered in the larger exocrine pancreas, which lies posteriorly in the upper abdomen. ('Exocrine' refers to glands which have ducts, and which are not covered in this book.) The endocrine pancreas secretes:

- 1 **insulin**, which regulates glucose and lipid metabolism;

- 2 **glucagon**, a counter-regulatory hormone to insulin that elevates blood glucose;

- 3 **somatostatin**, which regulates gastrointestinal motility;

- 4 **pancreatic polypeptide**, which regulates gastrointestinal secretion.

The ovary is the major female reproductive gland, and produces:

- 1 **estrogens**, which regulate reproductive function and secondary sexual characteristics;

- 2 **progesterone**, which stimulates endometrial vascularization and maintains pregnancy;

- 3 **relaxin**, a polypeptide also found in the placenta and uterus, which may be important in parturition by softening the cervix and relaxing the pelvic ligaments;

- 4 **inhibin**, which inhibits FSH production.

The placenta is the organ of pregnancy serving the developing fetus. Hormones produced by the placenta include:

- 1 **chorionic gonadotrophin** (CG; hCG; h = human) which maintains placental progesterone synthesis;

- 2 **placental lactogen** (PL);

- 3 **estriol**, the major form of estrogen secreted by the placenta;

- 4 **progesterone** which maintains the reproductive organs in pregnancy;

- 5 **relaxin**.

The testis is the major male reproductive gland, producing:

- 1 **testosterone** which controls reproductive function and secondary sexual characteristics;

- 2 **inhibin**, which inhibits FSH secretion;

- 3 **Müllerian inhibiting hormone** (MIH), a fetal hormone which dedifferentiates the Müllerian duct.

The gastrointestinal tract (GIT) is the largest endocrine organ and produces several autocrine, paracrine and endocrine hormones including:

- 1 **cholecystokinin** (CCK);

- 2 **gastric inhibitory peptide** (GIP);

- 3 **gastrin**;

- 4 **neurotensin**;

- 5 **secretin**;

- 6 **substance P**;

- 7 **vasoactive intestinal peptide** (VIP).

Adipocytes produce the peptide hormone **leptin** which is important in the control of feeding and energy expenditure.

The kidney produces hormones involved in the control of blood pressure and in erythropoiesis. **Renin** cleaves angiotensinogen to angiotensin I in the kidney and plasma. **Erythropoietin** stimulates production of red blood cells in the marrow.

The skin, liver and kidney produce vitamin D which has certain endocrine functions.


The heart produces atrial natriuretic peptide. **Circulating blood elements**, including macrophages, produce peptides such as the cytokines, which are involved in immune function.

The pineal gland is situated in the brain and is involved with rhythms, for example the reproductive rhythms of animals which breed seasonally. Its role in humans is not known for certain. The pineal gland produces **melatonin**.

Readers should be aware that putative endocrine hormones continue to be reported.

2

Chemical transmission



Classification of endocrine hormones

Hormones are chemical messengers. They may be classified several ways (Fig. 2a):

1 Autocrine: acting on the cells that synthesized them; for example insulin-like growth factor (IGF-1) which stimulates cell division in the cell which produced it.

2 Paracrine: acting on neighbouring cells. An example is insulin, secreted by pancreatic β cells and affecting secretion of glucagon by pancreatic α cells.

3 Endocrine: acting on cells or organs to which they are carried in the bloodstream or through another aqueous ducting system, such as lymph. Examples include insulin, estradiol and cortisol.

4 Neuroendocrine: this is really paracrine or endocrine, except that the hormones are synthesized in a nerve cell (neuron) which releases the hormone adjacent to the target cell (paracrine), or releases it into the bloodstream, which carries it to the target cell, for example from the hypothalamus to the anterior pituitary gland through the portal system.

5 Neural: this is neurotransmission, when a chemical is released by one neuron and acts on an adjacent neuron (Fig. 2b). These chemicals are termed neurotransmitters. Neurotransmitters produce virtually instantaneous effects, for example acetylcholine, whereas some chemicals have a slower onset but longer lasting effect on the target organ, and are termed **neuromodulators**, for example certain opioids.

6 Phomonal transmission is the release of volatile hormones, called pheromones, into the atmosphere, where they are transmitted to another individual and are recognized as an olfactory signal.

Basic principles of neurotransmission

When the nerve impulse arrives at the terminal, it triggers a calcium-dependent fusion of neurotransmitter packets or vesicles with the nerve terminal plasma membrane (Fig. 2b), followed by release of the neurotransmitter into the gap, or synapse, between the nerve cells. The neurotransmitters and neuromodulators bind to specific plasma membrane receptors, which

transmit the information that the neurotransmitter has brought to the receiving cell by means of other membrane proteins and intracellular 'second messengers'. The neurotransmitters are inactivated by enzymes or taken up into the nerve that released them and metabolized. The release of the neurotransmitter may be modulated and limited by: (i) autoreceptors on the nerve terminal from which it was released, so that further release of the neurotransmitter is inhibited; and (ii) by presynaptic inhibition, when another neurone synapses with the nerve terminal.

Chemical transport

The movement of chemicals between cells and organs is usually tightly controlled.

Diffusion is the movement of molecules in a fluid phase, in random thermal (Brownian) motion (Fig. 2c). If two solutions containing the same chemical, one concentrated and the other relatively dilute, are separated by a membrane which is completely permeable and passive, the concentrations of the chemical on either side of the membrane will eventually end up being the same through simple diffusion of solutes. This is because there are many molecules of the chemical on the concentrated side, and therefore a statistically greater probability of movement from the more concentrated side to the more dilute side of the membrane. Eventually, when the concentrations are equal on both sides, the net change on either side becomes zero. Lipophilic molecules such as ethyl alcohol and the steroids, for example estradiol, appear to diffuse freely across all biological membranes.

Facilitated transport is the transport of chemicals across membranes by carrier proteins. The process does not require energy and cannot, therefore, transport chemicals against a concentration gradient. The numbers of transporter proteins may be under hormonal control. Glucose is carried into the cell by transporter proteins (see Chapter 39) whose numbers are increased by insulin.

Active transport uses energy in the form of adenosine triphosphate (ATP) or other metabolic fuels. Therefore chemicals can be transported across the membrane against a concentration gradient, and the transport process can be interrupted by metabolic poisons.

Ion channels mediate active transport, and consist of proteins containing charged amino acids that may form activation

and inactivation 'gates'. Ion channels may be activated by receptors, or by voltage changes through the cell membrane. Channels of the ion Ca^{2+} can be activated by these two methods.


Osmosis is the passive movement of water through a semi-permeable membrane, from a compartment of low solute concentration to one which has a greater concentration of the solute. ('Solute' refers to the chemical which is dissolved in the 'solvent', usually water in biological tissues.) Cells will shrink or swell depending on the concentrations of the solutes on either side of the membrane.

Phagocytosis and pinocytosis are both examples of endocytosis. Substances can enter the cell without having to pass through the cell membrane. Phagocytosis is the ingestion or 'swallowing' of a solid particle by a cell, while pinocytosis is the ingestion of fluid. Receptor-mediated endocytosis is the ingestion of specifically recognized substances by coated pits. These are parts of the membrane which are coated with specific membrane proteins, for example clathrin.

Exocytosis is the movement of substances, such as hormones, out of the cell. Chemicals which are stored in the small vesicles or packets are secreted or released from the cell in which they are stored by exocytosis, when the vesicle fuses with the membrane.

Hormone transport in blood. When hormones are secreted into the blood, many are immediately bound to plasma proteins (Fig. 2d). The proteins may recognize the hormone specifically and bind it with high affinity and specificity, for example the binding of sex hormones by sex hormone-binding globulin (SHBG). Other proteins, such as albumin, also bind many hormones, including thyroid hormone and the sex hormones, with much lower affinity. Equilibrium is set up between the free and bound hormone, so that a fixed proportion of the hormone travels free and unbound, while most is carried bound. It is currently believed that only the free fraction of the hormone is physiologically active and available to the tissues and for metabolism. When a hormone is bound to plasma proteins it is physiologically inactive and is also protected from metabolic enzymes in organs such as the liver. Some drugs, such as aspirin, can displace other substances such as anticoagulants from their binding sites, which in the case of anticoagulants may cause haemorrhage.

3 Mechanisms of hormone action: I Membrane receptors



Clinical background

Acromegaly is usually caused by anterior pituitary gland tumours which secrete growth hormone. In 30 to 40% of cases, the tumour is thought to arise due to a somatic mutation affecting transmembrane signalling mechanisms. The stimulatory G-protein G_s is involved in signal transduction at the growth hormone releasing hormone receptor. Mutation of the α -subunit of G_s into the *gsp* oncogene prolongs the activation phase of the G-protein system, allowing unrestrained hormone synthesis and cell division. The distinctive clinical features of acromegaly and development of the pituitary tumour follow.

Introduction

Hormones interact with target cells through a primary interaction with receptors which recognize the hormones selectively. There are several different receptor systems, which vary in mechanism and timing (Fig. 3a). Charged ions such as peptides and neurotransmitters bind to receptors on the cell membrane. This causes a conformational change in other membrane proteins, which activate enzymes inside the cell, resulting in, for example, the synthesis of 'second messengers', which activate phosphorylating enzymes.

Uncharged molecules, such as the steroid hormones diffuse into the cell and bind to intracellular receptors (see Chapter 4). The hormone–receptor complex binds to specific hormone response elements (HRE) on the DNA; the result is that RNA and protein synthesis are altered. The cell will react faster to peptide hormones and neurotransmitters than it will to steroid hormones, which work through relatively slow changes in protein synthesis. Nevertheless, membrane receptors have been discovered for steroid hormones, although the significance of these is not yet clear.

Membrane receptors

Three regions can be distinguished in membrane receptors: the extracellular; the membrane-spanning; and the intracellular domains. The extracellular N-terminal domain has the hormone-binding domain, and also has glycosylation sites. The extracellular domain that binds the receptor is often rich in cysteine residues, which form rigid pockets in which the hormone is bound. The transmembrane region consists of one or more segments, made up of hydrophobic (uncharged) amino acids, arranged helically, whose role may include the anchoring of the receptor in the membrane. Different subunits within the membrane may be held together by means of disulphide linkages (e.g. the insulin receptor, Chapter 39). The intracellular domain is the effector region of the receptor, which may be linked with another membrane protein system, a set of enzymes which are guanosine triphosphatases (GTPases). The β -adrenergic receptor is an example of a G-protein-linked receptor. Another class, which includes the insulin receptor, has the intracellular domain as a tyrosine protein kinase. The intracellular region may also have a regulatory tyrosine or serine/ threonine phosphorylation site.

Second messengers

G protein linked receptors. These are protein receptors in the cell membrane, with an extracellular domain and an intracellular domain. The peptide chain that forms the protein always spans the membrane. When the hormone binds to the extracellular

domain, this causes a change in shape of the receptor. This causes the intracellular domain to activate G proteins. G proteins have three main parts: an α subunit, a β subunit and a γ subunit. When activated, firstly the α subunit substitutes a GDP molecule for a GTP molecule. This results in the activation of the G proteins. They can be either stimulatory or inhibitory, that is they can cause an increased level of enzyme activity or a decreased level of activity in the second messenger systems. Mutations of G proteins can occur and may result in disease (see Clinical scenario above).

Adenylate cyclase system. The hormone binds to the receptor, which activates a membrane G protein, which moves to the receptor (Fig. 3b). In the inactive state, the G protein binds GDP, which is exchanged for GTP, and a subunit of the G protein activates adenylate cyclase to convert ATP to the second messenger cyclic AMP. Adenylate cyclase is situated on the plasma membrane, but does not itself bind the hormone. Once formed in the cytoplasm, cAMP activates the catalytic subunit of a specific protein kinase (PKA), which forms part of a cascade of intracellular phosphorylations resulting in the cellular response. Since just one molecule of hormone can result in the production of many molecules of cAMP, this is a very efficient means of amplifying the receptor–hormone interaction. Once formed, cAMP is rapidly broken down by the enzyme phosphodiesterase. An example of a hormone operating through adenylate cyclase is epinephrine, through the adrenergic β -receptor.

Hormones can produce inhibitory effects on a cell, and this may be achieved through the fact that some G proteins, such as G_i, may inhibit adenylate cyclase, thus inhibiting the formation of cAMP. An example of this mechanism in action is the inhibition of adenylate cyclase through the binding of norepinephrine to the α -2-receptor on the presynaptic nerve terminal.

Inositol triphosphate system. In this system, the hormone–receptor–G-protein complex interaction triggers the membrane enzyme phospholipase C (PLC), which catalyses the hydrolysis of phosphoinositol (PIP₂) to two important metabolites, inositol triphosphate (IP₃) and diacylglycerol (DAG; Fig. 3c). IP₃ generates, from the endoplasmic endothelium, increased free Ca²⁺, which together with DAG promotes the activation and migration to the membrane of the enzyme protein kinase C (PKC). PKC may also be mobilized through the entry of Ca²⁺ into the cell. Examples of hormones and neurotransmitters which activate the system are **epinephrine** acting on α -1 receptors and **acetylcholine** on muscarinic cholinergic receptors. These systems are important clinically since they provide substantial numbers of possible targets for drugs.

Receptor antagonists

Receptor antagonism is an important aspect of endocrinology and drug use generally, not only in terms of the study of the hormone–receptor interaction, but also in therapeutic terms, since antagonists play a large part in the treatment of endocrine disease. The molecule which binds to the receptor and elicits the normal cellular response is termed the **agonist**. The ligand which binds, but elicits no response, is the **antagonist**. Antagonists act at the membrane in different ways. For example the β -receptor blocker propranolol competes with epinephrine at its binding site. The anticonvulsant phenytoin blocks ion channels.